Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Receivables (2016 - 2026)

Iradimed has reported Receivables over the past 14 years, most recently at $13.4 million for Q1 2026.

  • Quarterly Receivables rose 5.58% to $13.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.4 million through Mar 2026, up 5.58% year-over-year, with the annual reading at $13.7 million for FY2025, 29.47% up from the prior year.
  • Receivables was $13.4 million for Q1 2026 at Iradimed, down from $13.7 million in the prior quarter.
  • Over five years, Receivables peaked at $13.9 million in Q3 2025 and troughed at $6.5 million in Q1 2022.
  • The 5-year median for Receivables is $12.0 million (2024), against an average of $11.6 million.
  • Year-over-year, Receivables soared 158.43% in 2022 and then fell 18.92% in 2024.
  • A 5-year view of Receivables shows it stood at $13.3 million in 2022, then decreased by 7.91% to $12.2 million in 2023, then decreased by 13.65% to $10.6 million in 2024, then increased by 29.47% to $13.7 million in 2025, then fell by 1.84% to $13.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Receivables are $13.4 million (Q1 2026), $13.7 million (Q4 2025), and $13.9 million (Q3 2025).